TY - JOUR
T1 - Cutaneous CD30+ lymphoproliferative disorders
T2 - Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily
AU - Paulli, Marco
AU - Berti, Emilio
AU - Boveri, Emanuela
AU - Kindl, Sandra
AU - Bonoldi, Emanuela
AU - Gambini, Claudio
AU - Rosso, Renato
AU - Borroni, Giovanni
AU - Straccapansa, Vincenzo
AU - Magrini, Umberto
AU - Decoteau, John E.
AU - Krammer, Peter H.
AU - Möller, Peter
AU - Kadin, Marshall E.
PY - 1998
Y1 - 1998
N2 - The spectrum of CD30+ cutaneous lymphoproliferative disorders is characterized by the histology of a high-grade lymphoma but frequent clinical regression of skin lesions in lymphomatoid papulosis (LyP) and occasional regression in CD30+ large cell lymphomas (LCLs). A recent study shows that apoptosis may be a significant mechanism of regression of LyP (Arch Dermatol 133:828-833, 1997). Therefore, we studied expression of proteins that induce apoptosis, including CD27, CD40, CD95, and nerve growth factor receptor (NGF- R), as well as anti-apoptotic protein bcl-2 in skin lesions from 25 patients within the spectrum of CD30+ cutaneous lymphoma. Our results show consistent expression of CD95 (APO-1/Fas), but rare or absent expression of CD27, CD40, and NGF-R on tumor cells from both regressing LyP lesions and nonregressing CD30+ lymphomas. Bcl-2 was expressed at low levels in LyP and at high levels in pleomorphic CD30+ lymphomas. These results indicate that, in addition to CD30, CD95 expression is preferentially expressed at high levels in all cutaneous CD30+ lymphomas and suggest that CD95 may play a role in the regression of CD30+ skin lesions. Expression of bcl-2 appears to protect tumor cells from apoptosis in CD30+ lymphoproliferative disorders.
AB - The spectrum of CD30+ cutaneous lymphoproliferative disorders is characterized by the histology of a high-grade lymphoma but frequent clinical regression of skin lesions in lymphomatoid papulosis (LyP) and occasional regression in CD30+ large cell lymphomas (LCLs). A recent study shows that apoptosis may be a significant mechanism of regression of LyP (Arch Dermatol 133:828-833, 1997). Therefore, we studied expression of proteins that induce apoptosis, including CD27, CD40, CD95, and nerve growth factor receptor (NGF- R), as well as anti-apoptotic protein bcl-2 in skin lesions from 25 patients within the spectrum of CD30+ cutaneous lymphoma. Our results show consistent expression of CD95 (APO-1/Fas), but rare or absent expression of CD27, CD40, and NGF-R on tumor cells from both regressing LyP lesions and nonregressing CD30+ lymphomas. Bcl-2 was expressed at low levels in LyP and at high levels in pleomorphic CD30+ lymphomas. These results indicate that, in addition to CD30, CD95 expression is preferentially expressed at high levels in all cutaneous CD30+ lymphomas and suggest that CD95 may play a role in the regression of CD30+ skin lesions. Expression of bcl-2 appears to protect tumor cells from apoptosis in CD30+ lymphoproliferative disorders.
KW - Bcl-2
KW - CD30+ cutaneous lymphoproliferative disorders
KW - Fas (CD95)
UR - http://www.scopus.com/inward/record.url?scp=13144256770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13144256770&partnerID=8YFLogxK
M3 - Article
C2 - 9824099
AN - SCOPUS:13144256770
VL - 29
SP - 1223
EP - 1230
JO - Human Pathology
JF - Human Pathology
SN - 0046-8177
IS - 11
ER -